Home
Clinical Resources Search
PQI: Managing EGFR Inhibitor Induced Rash

Managing EGFR Inhibitor Induced Rash

Download PQI pdf 0.17MB

Last Updated: May 22, 2024

By: Sara Moran Smith, PharmD, BCOP

About this PQI

Rash occurs in approximately 90% of patients treated with epidermal growth factor receptor (EGFR) inhibitors1 with 10-20% developing severe eruption. 1 Studies have shown that the presence of this rash is indicative of response to treatment. 1 Therefore, it is important to prevent and manage this side effect appropriately in an effort to avoid holding or decreasing the dose of EGFR inhibitors.

More About This PQI

PQI:

Managing-Immunotherapy-Treatment-Related-Rash_PQI_NCODA pdf 0.16MB

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action PQI Podcast Toolkit Treatment Support Kit Video Rash Osimertinib Supportive Care Tagrisso

PQI

Frequently Searched

Supported by

Managing EGFR Inhibitor Induced Rash

About this PQI

More About This PQI

PQI:

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

Advances in MRD Monitoring for Diffuse Large B-Cell Lymphoma (DLBCL)

Epcoritamab (Epkinly®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

PQI: Ibrutinib Dosing Optimization

PQI: Zanubrutinib (Brukinsa®) Patient Selection and Management

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

PQI in Action: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancerwith MET Exon 14 Alterations

PQI in Action: Siltuximab (Sylvant®) in Patients with Idiopathic Multicentric Castleman Disease

PQI in Action: Isatuximab-irfc (Sarclisa®) in 1q21 Gain or Amplifications in Relapsed/Refractory Multiple Myeloma

The PQI Podcast S8 Bonus Episode: ¡No Más Melanomas! – Updates in the Treatment of Cutaneous Melanoma

S8 Ep 12: Lorlatinib in Practice: 5 Years of Data, Real-World Counseling, and AE Management

S8 Ep 11: Honoring Her Legacy: A Conversation with Miss America 2024

The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting

Readiness Tracker

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Treatment Support Kit: Tivozanib

Treatment Support Kit: Regorafenib

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

PQI: Managing Immunotherapy Treatment Related Rash

PQI: Osimertinib (Tagrisso®) In EGFR Positive Non-Small Cell Lung Cancer

The PQI Podcast S4 Ep 5: Role of Oncology Social Worker

The PQI Podcast S4 Ep 6 : Community Pharmacy and Ohio Board of Pharmacy

The PQI Podcast S4 Ep 9: Mental Illness and Burnout

The PQI Podcast S4 Ep 10: Oncology Wellness & Exercise

PQI: Osimertinib (Tagrisso®) In EGFR Positive Non-Small Cell Lung Cancer

Advances in MRD Monitoring for Diffuse Large B-Cell Lymphoma (DLBCL)

Epcoritamab (Epkinly®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

The PQI Podcast S8 Bonus Episode: ¡No Más Melanomas! – Updates in the Treatment of Cutaneous Melanoma

S8 Ep 12: Lorlatinib in Practice: 5 Years of Data, Real-World Counseling, and AE Management